Vybion, Inc
Transforming CNS delivery for gene therapy
We are developing a non-viral delivery platform using exosomes for central nervous system (CNS) therapies, with a focus on intranasal delivery to enable broad brain distribution. Recent data in ischemic stroke, Alzheimer’s disease, and Parkinson’s disease supports the potential of this approach for effective CNS targeting.
Vybion has demonstrated proof of concept in vitro and in animal models for its therapeutic candidate using AAV modality for targeting Huntington’s disease, along with Orphan Disease designation and prior engagement with the FDA. The platform is designed to deliver targeted genetic material to address underlying disease mechanisms associated with neurodegeneration. Costs are well over $1M per patient with AAV.
We believe exosome-based delivery represents a promising next-generation approach for CNS therapies, with potential advantages in safety, repeat dosing, and accessibility. The primary objective of this request is for formulation studies in nonhuman primates to identify optimized conditions for brain distribution in humans which have a distinct brain structure that deviates from rodents where current studies have been performed. Once these formulations studies are completed (4 months) IND enabling work will begin.
Fundraise Details
This section is only visible to registered investors. Log in or register as an accredited investor to view.
Ready to Ask For Funding for your company?
Post a Funding RequestKey Facts
- Industry
- {{model.industry | ffIndustry}}
- Location
- {{model.city_state}}
- Year Founded
- {{model.year_founded}}
- Monthly Income
- {{model.monthly_income | ffIncome}}
- Website
- {{model.homepage_url}}